Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 123,500 shares, a growth of 175.7% from the July 31st total of 44,800 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 13,700 shares, the short-interest ratio is currently 9.0 days.
Eupraxia Pharmaceuticals Trading Down 4.4 %
Shares of EPRX traded down $0.12 during midday trading on Thursday, hitting $2.50. The company had a trading volume of 8,030 shares, compared to its average volume of 17,138. The firm has a 50 day moving average price of $2.62. The stock has a market cap of $68.21 million and a PE ratio of -2.50. Eupraxia Pharmaceuticals has a 52 week low of $2.39 and a 52 week high of $5.58.
Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.17) earnings per share for the quarter.
Wall Street Analyst Weigh In
View Our Latest Research Report on EPRX
Institutional Investors Weigh In On Eupraxia Pharmaceuticals
An institutional investor recently bought a new position in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC acquired a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,000 shares of the company’s stock, valued at approximately $34,000.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- How Can Investors Benefit From After-Hours Trading
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.